Heterogeneity of Treatment Response to Asthma

Overview

Journal Adv Exp Med Biol

Specialties Biology
General Medicine

Date 2023 Jul 18

PMID 37464120

Authors

Tetsuro Maeda

Sandhya Khurana

Affiliations

Soon will be listed here.

Abstract

The definition of asthma has evolved over the years with significant heterogeneity of the disease increasingly recognized. Complex gene and environment interactions result in different pheno-endotypes of asthma that respond differently to the same treatment. Multiple studies have revealed pharmacogenomic and endophenotypic factors that predict treatment response to standard therapies for asthma. Recent advances in biologic medications have enabled a more tailored approach to the care of patients with moderate to severe asthma, taking into consideration clinical traits and measurable biomarkers. This chapter will review heterogeneity in treatment response to different medication classes for asthma: inhaled and systemic corticosteroids, beta-2 agonists, leukotriene modifiers, muscarinic antagonists, macrolides, and biologics.

Citing Articles

Interactions between epithelial mesenchymal plasticity, barrier dysfunction and innate immune pathways shape the genesis of allergic airway disease.

Brasier A Expert Rev Respir Med. 2025; 19(1):29-41.

PMID: 39745473 PMC: 11757041. DOI: 10.1080/17476348.2024.2449079.

References

Drazen J, Silverman E, Lee T . Heterogeneity of therapeutic responses in asthma. Br Med Bull. 2001; 56(4):1054-70. DOI: 10.1258/0007142001903535. View

Hall I . Pharmacogenetics of asthma. Eur Respir J. 2000; 15(3):449-51. DOI: 10.1034/j.1399-3003.2000.15.04.x. View

van Boven J, Dierick B, Usmani O . When biology meets behaviour: can medication adherence mask the contribution of pharmacogenetic effects in asthma?. Eur Respir J. 2021; 58(3). DOI: 10.1183/13993003.00304-2021. View

Wechsler M, Israel E . How pharmacogenomics will play a role in the management of asthma. Am J Respir Crit Care Med. 2005; 172(1):12-8. DOI: 10.1164/rccm.200412-1635OE. View

Meyers D, Bleecker E, Holloway J, Holgate S . Asthma genetics and personalised medicine. Lancet Respir Med. 2014; 2(5):405-15. PMC: 4768462. DOI: 10.1016/S2213-2600(14)70012-8. View

Haldar P, Pavord I, Shaw D, Berry M, Thomas M, Brightling C . Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med. 2008; 178(3):218-224. PMC: 3992366. DOI: 10.1164/rccm.200711-1754OC. View

Kelly R, Mendez K, Huang M, Hobbs B, Clish C, Gerszten R . Metabo-Endotypes of Asthma Reveal Differences in Lung Function: Discovery and Validation in Two TOPMed Cohorts. Am J Respir Crit Care Med. 2021; 205(3):288-299. PMC: 8886990. DOI: 10.1164/rccm.202105-1268OC. View

Malmstrom K, Guerra J, VILLARAN C, Pineiro A, Wei L, Seidenberg B . Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group. Ann Intern Med. 1999; 130(6):487-95. DOI: 10.7326/0003-4819-130-6-199903160-00005. View

Chan M, Leung D, Szefler S, Spahn J . Difficult-to-control asthma: clinical characteristics of steroid-insensitive asthma. J Allergy Clin Immunol. 1998; 101(5):594-601. DOI: 10.1016/S0091-6749(98)70165-4. View

10.

Martin R, Szefler S, King T, Kraft M, Boushey H, Chinchilli V . The Predicting Response to Inhaled Corticosteroid Efficacy (PRICE) trial. J Allergy Clin Immunol. 2007; 119(1):73-80. PMC: 2872157. DOI: 10.1016/j.jaci.2006.10.035. View

11.

Tantisira K, Lake S, Silverman E, Palmer L, Lazarus R, Silverman E . Corticosteroid pharmacogenetics: association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids. Hum Mol Genet. 2004; 13(13):1353-9. DOI: 10.1093/hmg/ddh149. View

12.

Dijkstra A, Koppelman G, Vonk J, Bruinenberg M, Schouten J, Postma D . Pharmacogenomics and outcome of asthma: no clinical application for long-term steroid effects by CRHR1 polymorphisms. J Allergy Clin Immunol. 2008; 121(6):1510-3. DOI: 10.1016/j.jaci.2008.04.015. View

13.

Tantisira K, Hwang E, Raby B, Silverman E, Lake S, Richter B . TBX21: a functional variant predicts improvement in asthma with the use of inhaled corticosteroids. Proc Natl Acad Sci U S A. 2004; 101(52):18099-104. PMC: 539815. DOI: 10.1073/pnas.0408532102. View

14.

Tantisira K, Lasky-Su J, Harada M, Murphy A, Litonjua A, Himes B . Genomewide association between GLCCI1 and response to glucocorticoid therapy in asthma. N Engl J Med. 2011; 365(13):1173-83. PMC: 3667396. DOI: 10.1056/NEJMoa0911353. View

15.

Hosking L, Bleecker E, Ghosh S, Yeo A, Jacques L, Mosteller M . GLCCI1 rs37973 does not influence treatment response to inhaled corticosteroids in white subjects with asthma. J Allergy Clin Immunol. 2013; 133(2):587-9. PMC: 3960323. DOI: 10.1016/j.jaci.2013.08.024. View

16.

Tantisira K, Damask A, Szefler S, Schuemann B, Markezich A, Su J . Genome-wide association identifies the T gene as a novel asthma pharmacogenetic locus. Am J Respir Crit Care Med. 2012; 185(12):1286-91. PMC: 3381232. DOI: 10.1164/rccm.201111-2061OC. View

17.

Sharma S, Kho A, Chhabra D, Qiu W, Gaedigk R, Vyhlidal C . Glucocorticoid genes and the developmental origins of asthma susceptibility and treatment response. Am J Respir Cell Mol Biol. 2014; 52(5):543-53. PMC: 4491138. DOI: 10.1165/rcmb.2014-0109OC. View

18.

Baines K, Simpson J, Wood L, Scott R, Fibbens N, Powell H . Sputum gene expression signature of 6 biomarkers discriminates asthma inflammatory phenotypes. J Allergy Clin Immunol. 2014; 133(4):997-1007. DOI: 10.1016/j.jaci.2013.12.1091. View

19.

Park H, Dahlin A, Tse S, Duan Q, Schuemann B, Martinez F . Genetic predictors associated with improvement of asthma symptoms in response to inhaled corticosteroids. J Allergy Clin Immunol. 2014; 133(3):664-9.e5. PMC: 4112383. DOI: 10.1016/j.jaci.2013.12.1042. View

20.

Xiao C, Biagini Myers J, Ji H, Metz K, Martin L, Lindsey M . Vanin-1 expression and methylation discriminate pediatric asthma corticosteroid treatment response. J Allergy Clin Immunol. 2015; 136(4):923-31.e3. PMC: 4586304. DOI: 10.1016/j.jaci.2015.01.045. View